Company news
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) news
Fulcrum Therapeutics, Inc. news releases on 6ix. Latest, Aug 17, 2026: Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance…
Press releases & updates
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
August 17, 2026
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
June 1, 2026
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
April 27, 2026
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
April 27, 2026
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
April 20, 2026
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
March 19, 2026
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
February 24, 2026
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
February 23, 2026
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
February 17, 2026
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 9, 2026
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 9, 2025
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
December 7, 2025
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 5, 2025
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
December 1, 2025
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
November 2, 2025
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
October 28, 2025
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
October 21, 2025
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
October 13, 2025
Fulcrum Therapeutics to Present at Upcoming Investor Meetings
August 25, 2025
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
July 29, 2025
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
July 28, 2025
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
July 27, 2025
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
May 28, 2025
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
May 28, 2025
Fulcrum Therapeutics to Participate in Upcoming May Conferences
May 7, 2025
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
April 30, 2025
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
April 23, 2025
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
March 3, 2025
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
February 24, 2025
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET
February 17, 2025
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 5, 2025
Fulcrum Therapeutics to Participate in Upcoming December Conferences
November 25, 2024
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
November 12, 2024
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
November 11, 2024
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
November 5, 2024
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
September 11, 2024
Fulcrum Therapeutics to Participate in Upcoming September Conferences
August 26, 2024
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
August 18, 2024
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
July 30, 2024
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
July 23, 2024
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
June 11, 2024
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
June 5, 2024
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 12, 2024
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 12, 2024
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
May 7, 2024
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
May 5, 2024
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
March 17, 2024
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
March 4, 2024